



Dalhousie University  
Industry Liaison and Innovation Office  
1379 Seymour St.  
Halifax, NS  
B3H 3M6

April 2, 2007

Attention: Executive Director

RE: License Agreement, Peterson Technology

Dear Mr. Layden,

Pacific Therapeutics Ltd. ("PTL") and Dalhousie University ("Dal") entered into a license agreement on April 20, 2007 for certain **technology related** to the US patents #5,985,592, #6,025,151 and #6,294,350.

PTL and Dal **agree** to amend the agreement as follows:

#### 5.02 MILESTONES

- a) Financing – [REDACTED] in capital  
or debt financing [REDACTED]

All of the other terms and conditions of the Agreement will remain in full force and effect and shall continue **for the duration of the term of the agreement. This letter** upon execution by both parties shall continue for the duration of the term of the Agreement and the two documents shall be read together.

If the foregoing amendment is satisfactory, please have this letter executed on behalf of Dal in the space provided and return a full executed copy to PTL.

<signature page to follow>



Yours truly

A handwritten signature in blue ink, appearing to read 'Doug Unwin'.

Doug Unwin  
President & CEO

Acknowledged and agreed to on behalf of  
Dalhousie University by:

A handwritten signature in blue ink, appearing to read 'W. Carl Breckenridge'.

---

Name:

**W. Carl Breckenridge**

Title:

**Vice-President Research  
Dalhousie University**

Date:

*May 6, 2008*



Dalhousie University  
Industry Liaison and Innovation Office  
1379 Seymour St.  
Halifax, NS  
B3H 3M6

June 27, 2008

Attention: Executive Director

RE: License Agreement, Peterson Technology

Dear Mr. Layden,

Pacific Therapeutics Ltd. (“PTL”) and Dalhousie University (“Dal”) entered into a license agreement on April 20, 2007 for certain technology related to the US patents #5,985,592, #6,025,151 and #6,294,350.

PTL and Dal agree to amend the agreement as follows:

#### 5.02 MILESTONES

- a) Financing – Securing [REDACTED] or debt financing – by [REDACTED]
- b) Clinical Studies – Enrolment of first patient in a clinical [REDACTED] 2008;

All of the other terms and conditions of the Agreement will remain in full force and effect and shall continue for the duration of the term of the agreement. This letter upon execution by both parties shall continue for the duration of the term of the Agreement and the two documents shall be read together.

If the foregoing amendment is satisfactory, please have this letter executed on behalf of Dal in the space provided and return a full executed copy to PTL.

<signature page to follow>

PACIFIC THERAPEUTICS LTD.  
1023 – 409 GRANVILLE STREET, VANCOUVER, BC, V6C 1T2  
P: (604) 738-1049 F: (604) 738-1094



PACIFIC  
THERAPEUTICS

Yours truly

Doug Unwin  
President & CEO

Acknowledged and agreed to on behalf of  
Dalhousie University by:

Name: \_\_\_\_\_

Title: Vice President Research.

Date: July 9, 2008



Dalhousie University  
Industry Liaison and Innovation Office  
1379 Seymour St.  
Halifax, NS  
B3H 3M6

March 3, 2009

Attention: Executive Director

RE: License Agreement, Peterson Technology

Dear Mr. Layden,

Pacific Therapeutics Ltd. ("PTL") and Dalhousie University ("Dal") entered into a license agreement on April 20, 2007 for certain technology related to the US patents #5,985,592, #6,025,151 and #6,294,350.

PTL and Dal agree to amend the agreement as follows:

#### 5.02 MILESTONES

- a) Financing – [REDACTED] million dollars (\$2,000,000) in capital or debt financing
- b) Clinical Studies – Enrolment of first patient in [REDACTED]

#### 5.01 PAYMENTS


- e) a payment of [REDACTED] to the licensee or a [REDACTED] clinical trial (or its equivalent in a major market country);

- f) [REDACTED]

All of the other terms and conditions of the Agreement will remain in full force and effect and shall continue for the duration of the term of the agreement. This letter upon execution by both parties shall continue for the duration of the term of the Agreement and the two documents shall be read together.

If the foregoing amendment is satisfactory, please have this letter executed on behalf of Dal in the space provided and return a full executed copy to PTL.


Yours truly



Doug Unwin  
President & CEO

Acknowledged and agreed to on behalf of  
Dalhousie University by:

Name:



Title:

**Dr. Martha Crago**  
**Vice-President Research**  
**Dalhousie University**

Date:

3/24/09



Dalhousie University  
Industry Liaison and Innovation Office  
1379 Seymour St.  
Halifax, NS  
B3H 3M6

January 18, 2010

Attention: Executive Director

RE: License Agreement, Peterson Technology

Dear Mr. Layden,

Pacific Therapeutics Ltd. ("PTL") and Dalhousie University ("Dal") entered into a license agreement on April 20, 2007 for certain technology related to the US patents #5,985,592, #6,025,151 and #6,294,350.

PTL and Dal agree to amend the agreement as follows:

#### 5.02 MILESTONES

a)

b)

#### 5.01 PAYMENTS

c)  
will  
fee  
end

All of the other terms and conditions of the Agreement will remain in full force and effect and shall continue for the duration of the term of the agreement. This letter upon execution by both parties shall continue for the duration of the term of the Agreement and the two documents shall be read together.

PACIFIC THERAPEUTICS LTD.  
1023 – 409 GRANVILLE STREET, VANCOUVER, BC, V6C 1T2  
P: (604) 738-1049 F: (604) 738-1094

If the foregoing amendment is satisfactory, please have this letter executed on behalf of Dal in the space provided and return a full executed copy to PTL.


In addition PTL will pay Dal a one-time license amendment fee of two thousand dollars (\$2,000) upon execution of this document.

Yours truly,



Doug Unwin  
President & CEO

Acknowledged and agreed to on behalf of  
Dalhousie University by:



---

Name: **Dr. Martha Crago**  
Title: **Vice-President Research**  
**Dalhousie University**

Date: Jan 25, 2010